版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
ChronicObstructivePulmonaryDisease
andAsthmaUpdate
JohnL.Faul,MDFCCPAssistantProfessor,DivisionofPulmonary/CriticalCareMedicineStanfordUniversity.ChronicObstructivePulmonaryCOPD:OutlineEpidemiologyDefinitionsMedicalmanagementHypoxiaInfectionsVaccination
.COPD:OutlineEpidemiology.UniversalProblem
.UniversalProblem
.COPD:epidemiology14millionintheUSwithCOPD12.5millionwithchronicbronchitis1.65millionwithemphysema4thleadingcauseofdeathinUS3rdmostfrequentdiagnosisofpatientsreceivinghomecare.COPD:epidemiology14millioniPrevalenceofCOPDintheUS*Age-adjustedto2000USpopulation.†Representsastatisticallysignificantdifferencefromrateamongmales.Manninoetal.MMWR.2002;51(SS-6):1-16.Rate/1,000Population*020304050607080901980198219841986YearMaleFemaleTotal101988199019921994199619982000Since1987,theprevalenceofCOPDamongwomenhasbeensignificantlyhigherthanthatamongmen†††††††††††††††.PrevalenceofCOPDintheUS*ACOPD:
TheUsualSuspects.COPD:
TheUsualSuspects.COPD:riskfactorstobaccosmokingaccountsfor80-90%oftheriskofdevelopingCOPDageofstarting,totalpack-yearsandcurrentsmokingstatusarepredictiveofmortalityonly15%ofsmokersdevelopclinicallysignificantCOPDalpha1-antitrypsindeficiency(accountsforlessthan1%ofallCOPDcases)occupationalexposurestodustsandfumes.COPD:riskfactorstobaccosmokLungfunctiondeclineswithage.LungfunctiondeclineswithagElastictissueislostinemphysema.ElastictissueislostinemphCOPD:definitionsChronicbronchitis---aclinicaldefinition:“thepresenceofchronicproductivecoughfor3monthsineachof2successiveyearsinapatientinwhomothercausesofchroniccoughhavebeenexcluded”Emphysema---apathologicdefinition:“abnormalpermanentenlargementoftheairspacesdistaltotheterminalbronchiolesaccompaniedbydestructionoftheirwalls”.COPD:definitionsChronicbronc
Pinkpuffers
&
Bluebloaters
.
Pinkpuffers
&
BlueCOPD:HyperinflationIncreasedretrosternalairspaceFlatdiaphragmsIncreasedAPdiameter.COPD:HyperinflationIncreasedCOPD.COPD.COPD:OxygentherapyOxygentherapyinCOPD:extendslifeinhypoxemicpatientsNOTTtrial,AnnIntMed1980;93:391-398MRCtrial,Lancet1981;1:681-685strengthenscardiacfunction,improvesexerciseperformanceandADLswhenFEV1<1.0L(or<50%predicted)an ABGshouldbedoneHomeO2costsintheUS/yr:$2,400,000,000.COPD:OxygentherapyOxygentheOxygenDissociationCurve1008060BelowPaO2=60mmHg,Hemoglobinrapidlylosesoxygencarryingcapacity (West:TextbookofPhysiology)
HemoglobinSaturation%406080__________40__200iiiAt80mmHg,95%satAt60mmHg,90%satAt40mmHg,70%satPaO2(mmHg).OxygenDissociationCurve10080HypoxicPulmonaryVasoconstrictionThelungregulatesbloodflowaccordingtoitsoxygencontentAlowvenousoxygencontent(lowoxygencontentinthepulmonaryartery)preventsbloodflowtothelungBloodFlow%Airsack(Alveolar)OxygenWest:TextbookofPhysiologyOxygen-sensitivechemoreceptorslocatedinthepulmonaryarteriolearethedominantcontrollersofpulmonaryvasculartone FishmanAP:Hypoxiaonthepulmonarycirculation.Howandwhereitacts. CircRes1976;38:221–231.HypoxicPulmonaryVasoconstricCOPD:acaseinpointCC:Mrs.H.isa67y.ofemalewith worseningdyspneaxseveralyearswhopresentsfor2ndopinionregardingdiagnoses,andmanagement,ofher“breathingproblem”herpastdiagnoseshaveincludedasthma,bronchitis,andemphysemashewantstoknowexactlywhatshehas....COPD:acaseinpointCC:MrsCOPD:acaseinpointHerdyspneaismuchworseinthelastyear,tothepointthatshecannolongerbatheorcookwithouthelp...Shehasanoccasionalcough,productiveofscantsputum...Shesmoked2ppdx40yearsbutquit6yearsago....COPD:acaseinpointHerdyspnCOPD:acaseinpointShetakesthefollowingmedications:albuterolMDI2-4puffsQIDandprnthisisher“favorite”medicineatroventMDI2puffsQIDshe’snotsurethisonehelps,butmaybetheophylline200mgBIDsomedoctorgaveherthis“yearsago”prednisone10mgQDcontinuouslyfor3yearswithoccasionalincreasesshe’snevertakenanyestrogenreplacement.COPD:acaseinpointShetakesCOPD:acaseinpointShe’stakesantibiotics6-7times/yearwhenherbreathing“getsreallybad”She’sbeenon
oxygen
butdoesn’tlikeitShe’stooshortofbreathtodoanyexerciseShehasbeeninthehospital4timesinthelastyearandwasintubatedonce,6monthsagoHPI:.COPD:acaseinpointShe’stakExacerbationofCOPD
Anthonisenetal,AnnIntMed1987;106:196Saintetal,JAMA1995;273(12):957If2of3followingcriteriaaremet:increasingdyspneaincreasedsputumvolumeincreasedsputumpurulence.ExacerbationofCOPD
If2of3ExacerbationofCOPD
NoninfectiousandinfectiousInfectionsincludeviralControversialifallsputumculturesarecausativeForpatientswith2orespecially3cardinalfeatures,antibioticsareusefulShortcoursesofantibioticsareuseful AmsdenGWetal.,Chest2003:123:772-777.ExacerbationofCOPD
NoninfecAntimicrobialTherapyOralagentsusedearlierintherapyMonotherapyusedwheneverpossiblePatientcompliance(once-dailydosing)Comprehensivediseasemanagement.AntimicrobialTherapyOralagenVaccinationsandCOPD
Annualinfluenzavaccine:Reductionsinexacerbationratesparticularlywithin3weeks.Noevidenceofaneffectofintranasalliveattenuatedviruswhenthiswasaddedtoinactivatedintramuscularvaccination.
Pneumococcalvaccineevery5yearsNoevidencethatpneumococcalvaccinereducestheseverityofCOPDPoolePJ.CochraneDatabaseSystRev.2000;(4):CD002733.LeechJA.CMAJ.1987:136(4):361-5.
.VaccinationsandCOPD
AnnualiCOPD:oralsteroidsforERdischargesAaronSD.NEnglJMed.2003;348(26):2618-25.
%relapsefreeDayn=147,Pred40/dayfor10days***.COPD:oralsteroidsforERdisVladtheInhaler.VladtheInhaler.COPD:inhaledsteroidsandLABACalverleyP.Lancet.2003Feb8;361(9356):449-56ChangeInFEV1(ml)
n=1465******.COPD:inhaledsteroidsandLABPeakFlowRates
Tiotropium
versus
Salmeterol
DonohueJFChest2002.122:47-55.
.PeakFlowRates
Tiotropium
vCOPD:smokingcessationTobaccosmokingisthemostimportantfactorinCOPD,andstoppingsmokingistheonlyinterventionknowntomodifythenaturalhistoryofairwaysobstruction..COPD:smokingcessationTobaccoCOPD:smokingcessation%abstinence**TonstadS.EurHeartJ.2003May;24(10):946-55..COPD:smokingcessation%absti
COPD:advancedtherapiesBullectomyLungvolumereductionsurgery(LVRS)TransplantationSurgeryforemphysema:.
COPD:advancedtherapiesBulleGOLD’03ClassificationofCOPD*respiratoryfailure:PaO2<60mmHgwithorw/oPaCO2>50mmHg.GOLD’03ClassificationofCOTherapyatEachStageofCOPDGoldUpdate2003*FEV1/FVC<70%.TherapyatEachStageofCOPDG
COPD:managementStopsmokingLong-termoxygenInhaledsteroidsandlong-actingbetaagonistsDietandexerciseTreatacuteexacerbationsMonitorlungfunctionVaccinate.
COPD:managementStopsmoking.AsthmaFactsintheUnitedStatesAnnualnumberofhospitalizations:478,000Annualnumberofdeathsfromasthma:4,657Annualnumberofworkdayslost:14.5millionAnnualnumberofschooldayslost:14millionEstimateddirectandindirectmedicalcosts:$16billion(needsvalidation)MorbMortalWklyRep.2002March29;51:1-13..AsthmaFactsintheUnitedStaSmoothMuscleDysfunctionAirway
InflammationInflammatoryCellActivationMucosalEdemaProliferationEpithelialDamageB.MembraneThickeningBronchoconstrictionBronchialHyperreactivityHypertrophyHyperplasiaSymptoms/ExacerbationsAsthmaPathophysiology.SmoothMuscleAirway
InflammatFlow(l/s)Vol(l)-20-41324521345-6Pre-albuterolPost-albuterolPredictedSpirometry.Flow(l/s)Vol(l)-20-413245213EosinophilsinHumanBronchi.EosinophilsinHumanBronchi.ChangesinEG2duringFPtherapy
FaulJL,Thorax1998.53,753-61.ChangesinEG2duringFPtheraChangeinMeanPeakFlowwiththerapyHaahtelaT.NEnglJMed1994,331:700.ChangeinMeanPeakFlowwithChangeinMeanPeakFlowwiththerapyGreeningAP.Lancet1994,344:219-24.ChangeinMeanPeakFlowwithStudyDayProbability
ofRemainingintheStudy1.00.80.60.40.2Sal/FP100/50
FP100
Salmeterol50
Placebo*3%0 7 14 21 28 35 42 49 56 63 70 77 11%35%49%ComparisonofAsthmaTherapiesKavuruMetal.JAllergyClinImmunol.2000;105:1108-1116..StudyDayProbability
ofRemaiTimetoFirstExacerbation*10095908580750 2 4 6 8 10 12 14 16 18 20 22 24TimetoFirstExacerbation(weeks)Exacerbation-Free
Patients(%)FP88mcgb.i.d.+Salmeterol
FP220mcgb.i.d.MatzJetal.JAllergyClinImmunol.2000;105:162S..TimetoFirstExacerbation*100Kavuruetal.JAllergyClinImmunol.2000;105:1108-1116.
Dataonfile,GlaxoWellcomeInc.WeekMeanChange
fromBaseline
inFEV1(%)3025201510500 2 4 6 8 10 12 Endpoint15%
[0.28L]5%
[0.11L]2%
[0.01L]Sal/FP100/50FP100Salmeterol50Placebo25%
[0.51L]**P0.008vsFP100,salmeterol50,andplaceboatendpoint.Dosesinmcgb.i.d.PatientsTreatedWithADVAIR™Diskus®100/50hadaSignificantlyGreaterImprovementinFEV1.Kavuruetal.JAllergyClinINoonanetal.AmJRespirCritCareMed.1999;159(3):640.Reissetal.ArchInternMed.1998;158:1213-1220.FEV1(%
ChangefromBaseline;Mean
±SE)StudyWeeks(Postrandomization)302520151050-5036912151923313947526068768492100108116124132140CumulativeExtensionPlaceboMontelukastBeclomethasonePrimaryStudyPatients(15Years)NotControlledonPRNBeta-Agonists
ImprovedFEV1(Study1andExtension).Noonanetal.AmJRespirCritProportion
ofPatients
WithoutAsthmaAttackDaysSinceRandomizationBeclomethasone(n=248)Montelukast(n=379)Placebo(n=253)P=0.006MontelukastvsplaceboP=0.001BeclomethasonevsplaceboP=0.129Montelukastvsbeclomethasone10.950.900.850.800.750.700102030405060708090Patients(15Years)NotControlledonPRNBeta-Agonists
Malmstrometal.AnnInternMed.1999;130:487-495.Inthisstudy,allpatientsbenefitedfrommandatoryuseofspacers,enforcedcompliance,andrigorousmonitoringofpatients.Proportion
ofPatients
WithoutAnti-IgEAsthmaTherapiesruhMAbE-25****NS*MilgromH.NEnglJMed.199923;341(26):1966-73.Sx.Anti-IgEAsthmaTherapiesruhMASTHMA:acaseinpointCC:Ms.B.isa22
y.ofemalewith episodicdyspneax2yearswhopresentsfor2ndopinionregardingdiagnoses,andmanagement,ofher“breathingproblem”herpastdiagnoseshaveincludedasthma,bronchitis,andallergiesshewantstoknowexactlywhatshehas....ASTHMA:acaseinpointCC:MASTHMA:acaseinpointHerdyspneaismuchworseinthelastyear,tothepointthatsheoccasionallyhastoskipclassandonceshehashadtogototheED...Shehasanoccasionalcough,productiveofgreensputum...Sheneversmokedsheisallergictopollenandcats...She’saStanfordstudentwhoeatsa“healthydietandtakeslotsofvitamins”.ASTHMA:acaseinpointHerdysAcaseinpointShetakesthefollowingmedications:albuterolMDI2-4puffsQIDandprnthisisher“favorite”medicineprednisone10mgQDsheisjustfinishingasteroidtaperthatwasprescribedafterhermostrecentEmergencyRoomvisitshe’snevertakenanysteroidinhaler,becausetheydon’tworkandshe’sfearfuloftheiradverseeffects.AcaseinpointShetakesthefCOPD:acaseinpointShe’stakesantibiotics5times/yearwhenherbreathing“getsreallybad”ShesometimeswheezesafterexerciseShehasbeenintheED4timesinherlifetime,wasadmittedonce,buthasnotbeenintubatedHPI:.COPD:acaseinpointShe’stakConsiderationsinAsthmaTherapyEfficacyConvenienceControlAdverseeffects.ConsiderationsinAsthmaTheraAdverseeffectsofAsthmaTherapyBetaagonists:tremor,tachycardiaInhaledsteroids:Voice,Bones,?MetabolicLKRAs:HeadachePrednisone:Cushing’ssyndrome.AdverseeffectsofAsthmaTher012340130135140145140145150012346.56.05.55.04.50.0Time(yrs)Time(yrs)StandingHeight(cm)Standing-heightVelocity(cm/yr)NEnglJMed2000;343:1054-63.BudesonideNedocromilPlaceboBudesonideNedocromilPlaceboLong-TermEffectsofBudesonideorNedocromilinChildrenwithAsthma.012340130135140145140145150012TheRuleofTwos
(WhoNeedsControllerTherapy)Twobeta-agonistcanisters/yearTwodosesofbeta-agonist/weekTwonocturnal
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 高一年级数学统计图表综合应用习题课教学设计
- 初二年级心理健康教学设计:学会学习-我的学习策略工具箱
- 初中综合实践活动七年级上册“美味吃出健康来·大厨新体验”教学设计
- 小学四年级美术《点的魅力》教学设计:基于视觉语言重构的核心素养实践
- 初中语文七年级上册字音字形全复习教案
- 高中政治必修三《科学立法》议题式教学设计
- 初中二年级物理光现象章末复习教学设计
- 初中生物七年级上册《动物细胞》教学设计
- 高中生物高三二轮复习《生物的变异与进化》专题教学设计
- 高一英语教学设计:必修二 Unit 1 课时1 单元导入与阅读教学实践
- 《医疗器械经营质量管理规范》培训试题及答案
- 2026秋小学英语人教 PEP(三起)四年级上册语法基础易错题练习试题附答案(三套)
- 2026年电池PACK装配工考试试题(含答案)
- (一诊)绵阳市2024级高三第一次诊断性考试英语试卷B卷(含答案及解析)+听力音频
- 2026年河南省巩义市高一化学上册期末考试检测卷含完整答案(全优)
- 手术部位标识管理规范
- 2026云南小龙潭矿务局招聘125人易考易错模拟试题(共500题)试卷后附参考答案
- 2026秋新教科版科学四年级上册教学课件:第三单元 第5课 设计我们的乐器
- XX工程科技创新与“四新技术”应用方案
- 2026年锂电池回收与梯次利用项目可行性研究报告
- 静电粉末喷涂岗位安全操作手册
评论
0/150
提交评论